^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TNFRSF13C (TNF Receptor Superfamily Member 13C)

    i
    Other names: TNFRSF13C, TNF Receptor Superfamily Member 13C, BAFFR, CD268, Tumor Necrosis Factor Receptor Superfamily Member 13C, BLyS Receptor 3, BAFF Receptor, BAFF-R, Tumor Necrosis Factor Receptor Superfamily, Member 13C, B Cell-Activating Factor Receptor, B-Cell-Activating Factor Receptor, CD268 Antigen, Prolixin, BROMIX, CVID4, BR3
    11d
    Leniolisib for Immune Dysregulation in CVID (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Pharming Technologies B.V. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PTEN (Phosphatase and tensin homolog) • CD20 (Membrane Spanning 4-Domains A1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • IKZF1 (IKAROS Family Zinc Finger 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CARD11 (Caspase Recruitment Domain Family Member 11) • NFKB2 (Nuclear Factor Kappa B Subunit 2) • TNFRSF13C (TNF Receptor Superfamily Member 13C) • CD81 (CD81 Molecule) • SEC61A1 (SEC61 Translocon Subunit Alpha 1) • TNFRSF13B (TNF Receptor Superfamily Member 13B)
    27d
    The H159Y Variant of the BAFF-R Gene (TNFRSF13C) Is Unrelated to the Risk of Developing Systemic Lupus Erythematosus and Sjögren's Disease in a Mexican Population. (PubMed, Int J Mol Sci)
    This variant does not confer risk to SLE or SjD in the Mexican population. However, the heterozygous genotype may be associated with high levels of sBAFF in SLE patients.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF13C (TNF Receptor Superfamily Member 13C)
    2ms
    Differential Transcriptomic Features of Peripheral Blood Mononuclear Cells in Pulmonary Sarcoidosis with and Without Extrapulmonary Lesions in an East Asian Population. (PubMed, Biomedicines)
    These findings elucidate the mechanisms underlying granuloma formation in sarcoidosis and demonstrate the differential transcriptomic features of PBMCs in patients with and without EPL. The upregulation of IFNG and IFNLR1 may be related to EPL development and could serve as potential therapeutic targets for sarcoidosis.
    Journal
    |
    JAK2 (Janus kinase 2) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CLEC7A (C-Type Lectin Domain Containing 7A) • GBP5 (Guanylate Binding Protein 5) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • MMP9 (Matrix metallopeptidase 9) • CD40LG (CD40 ligand) • IL15 (Interleukin 15) • IL1B (Interleukin 1, beta) • TNFRSF13C (TNF Receptor Superfamily Member 13C) • SOCS3 (Suppressor Of Cytokine Signaling 3)
    2ms
    Bispecific BAFF-R/BCMA CAR T cells control growth of heterogeneous plasma cells in multiple myeloma. (PubMed, Mol Ther)
    In vivo, the dual CAR compensated for BCMA downregulation when BAFF-R was expressed, preventing the evolution of antigen escape-mutants that drive resistance to CAR T cell therapy. Our study proposes BAFF-R as a complementary target antigen suitable to eliminate malignant plasma cells with less advanced differentiation, lack of BCMA, and occurrence in dismal prognosis patients.
    Journal • IO biomarker
    |
    TNFRSF13C (TNF Receptor Superfamily Member 13C)
    5ms
    Identification of tumor associated neutrophils-related genes in triple-negative breast cancer for predicting prognosis and therapeutic response through integrated single-cell analysis. (PubMed, Front Immunol)
    Our study revealed RASGRP4, TIMM10B, and TNFRSF13C as promising therapeutic targets in TNBC. Targeting these TAN-associated genes may disrupt pro-tumor immune responses, suggesting novel strategies to improve patient outcomes.
    Journal
    |
    TNFRSF13C (TNF Receptor Superfamily Member 13C)
    5ms
    Aging-related signature stratifies LUAD prognosis and uncovers senescence-induced chemoresistance via NF-κB/RELA activation. (PubMed, Respir Res)
    This study established a clinically relevant aging-related signature for risk stratification in LUAD and provides mechanistic insights into how aging-driven cellular senescence promotes chemoresistance through RELA/NF-κB pathway activation. Targeting NF-κB signaling may represent a promising therapeutic approach to overcome senescence-associated chemoresistance and improve outcomes for LUAD patients.
    Journal
    |
    CCL20 (C-C Motif Chemokine Ligand 20) • TNFRSF11A (TNF Receptor Superfamily Member 11a) • TNFRSF13C (TNF Receptor Superfamily Member 13C) • H2AX (H2A.X Variant Histone) • IGFBP1 (Insulin Like Growth Factor Binding Protein 1) • RELA (RELA Proto-Oncogene) • TFAP2A (Transcription Factor AP-2 Alpha)
    |
    paclitaxel • bleomycin
    5ms
    Cgas deficiency promotes tumor growth by supporting B cell persistence and angiogenesis. (PubMed, Cell Immunol)
    cGAS deficiency fosters tumor growth by reducing the antitumor response, promoting a pro-tumor microenvironment, and supporting B cell survival. The Cgas-/- B cells enhance angiogenesis and are resistant to B cell depletion, contributing to tumor progression.
    Journal
    |
    CD8 (cluster of differentiation 8) • STING (stimulator of interferon response cGAMP interactor 1) • IL10 (Interleukin 10) • TLR9 (Toll Like Receptor 9) • TGFB1 (Transforming Growth Factor Beta 1) • TLR7 (Toll Like Receptor 7) • TNFRSF13C (TNF Receptor Superfamily Member 13C)
    11ms
    Identification and characterization of the tumor necrosis factor receptor superfamily in the Chinese tree shrew (Tupaia belangeri chinensis). (PubMed, BMC Genomics)
    TNFRSF exerts antiviral function most probably through the activation of the NF-κB pathway, subsequently causing apoptosis of infected cells. Our findings provide evolutionary and functional insights into tTNFRSF, indicating its potential utility in human viral infection models.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CD79A (CD79a Molecule) • TNFRSF13C (TNF Receptor Superfamily Member 13C)
    1year
    Transcriptomic Profiling Reveals Key Biomarkers in Primary Refractory and Early Relapse Classical Hodgkin Lymphoma (ASH 2024)
    Furthermore, increased activity of macrophages and reduced expression of B-cells support previous studies underlining their involvement in treatment resistance. Despite limitations in sample size, these findings shed light on the mechanisms behind resistance and early relapse in cHL, which could help guide the development of targeted therapies and potentially improve early risk assessment.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • JAK1 (Janus Kinase 1) • CD22 (CD22 Molecule) • PAX5 (Paired Box 5) • CD68 (CD68 Molecule) • CD79A (CD79a Molecule) • CSF1R (Colony stimulating factor 1 receptor) • CCL3 (C-C Motif Chemokine Ligand 3) • MS4A1 (Membrane Spanning 4-Domains A1) • TNFRSF13C (TNF Receptor Superfamily Member 13C) • BLNK (B Cell Linker) • C1QB (Complement C1q B Chain) • POU2AF1 (POU Class 2 Homeobox Associating Factor 1) • TLR2 (Toll Like Receptor 2)
    |
    PD-L1 expression • CD22 expression
    |
    nCounter® PanCancer Immune Profiling Panel
    over1year
    Genes Co-Expressed with ESR2 Influence Clinical Outcomes in Cancer Patients: TCGA Data Analysis. (PubMed, Int J Mol Sci)
    Finally, we investigated genes displaying similar expression patterns as ESR2 in tumor tissues, identifying potential co-expressed genes that may exert a synergistic effect on clinical outcomes, with significant results, including the expression of ACIN1, SYNE2, TNFRSF13C, and MDM4. Collectively, our results highlight the significant influence of ESR2 mRNA expression on the transcriptomic landscape and the overall metabolism of cancerous cells across various tumor types.
    Clinical data • Journal
    |
    MDM4 (The mouse double minute 4) • TNFRSF13C (TNF Receptor Superfamily Member 13C)
    almost2years
    Naive and regulatory B-cell transcription patterns guide the increased risk of papillary thyroid carcinoma in obesity. (PubMed, Cell Mol Biol (Noisy-le-grand))
    Notably, both of the gene expressions in naive and regulatory B-cells showed high similarity in both diseases. Our data reveals the high frequency of PTC in obese populations may be explained by the comparable transcriptional patterns of naive and regulatory B-cells, and offers novel insights for the analysis of critical genes and underlying biological mechanisms for obesity and PTC.
    Journal
    |
    TNFRSF13C (TNF Receptor Superfamily Member 13C)
    2years
    Single-cell and bulk RNA sequencing analysis of B cell marker genes in TNBC TME landscape and immunotherapy. (PubMed, Front Immunol)
    Notably, substantial differences between the higher and lower- BCMG score groups were observed in terms of immune cell infiltration, immune cell activity, tumor mutational burden, TIDE score, and the expression of immune checkpoint blockade genes. This study has established a robust model based on B-cell marker genes in TNBC, which holds significant potential for predicting prognosis and response to immunotherapy in TNBC patients.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CCND2 (Cyclin D2) • GZMB (Granzyme B) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • SEL1L3 (SEL1L family member 3) • HSPA6 (Heat Shock Protein Family A (Hsp70) Member 6) • TNFRSF13C (TNF Receptor Superfamily Member 13C)